Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Additional file 1: of Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

Marcus Vetter (3422660)
Julia Landin (5997692)
Barbara Szczerba (5997695)
Francesc Castro-Giner (5659600)
Sofia Gkountela (191896)
Cinzia Donato (5997698)
Ilona Krol (5997701)
Ramona Scherrer (5997704)
Catharina Balmelli (5997707)
Alexandra Malinovska (5997710)
Alfred Zippelius (805066)
Christian Kurzeder (5997713)
Viola Heinzelmann-Schwarz (390410)
Walter Weber (5997716)
Christoph Rochlitz (190083)
Nicola Aceto (5997719)

November 2018

Table S1. Drug classification. The table shows the drug classification used for the analysis, groupi...

Additional file 2: of Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Giampaolo Bianchini (516649)
Astrid Kiermaier (3739423)
Giulia Bianchi (3739441)
Young-Hyuck Im (2266708)
Tadeusz Pienkowski (3739432)
Mei-Ching Liu (3739429)
Ling-Ming Tseng (526534)
Mitch Dowsett (645)
Lila Zabaglo (3537764)
Sarah Kirk (3739426)
Tania Szado (3739435)
Jennifer Eng-Wong (3739438)
Lukas Amler (73009)
Pinuccia Valagussa (58502)
Luca Gianni (516651)

February 2017

Figure S1. Relationship between biomarkers and pCR by treatment group and estrogen receptor status. ...

Additional file 5: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Figure S3. Effect of 14 single genes on pathological complete response (pCR) adjusting for clinicopa...

Additional file 1: of A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Patrick Schöffski (125074)
Sara Cresta (5722382)
Ingrid Mayer (5722385)
Hans Wildiers (146595)
Silvia Damian (5722388)
Steven Gendreau (3350078)
Isabelle Rooney (5722391)
Kari Morrissey (5722394)
Jill Spoerke (5722397)
Vivian Ng (38767)
Stina Singel (5722400)
Eric Winer (5722403)

September 2018

Table S1. All-grade AEs related to any study drug occurring in ≥ 15% of all patients and correspondi...

Additional file 4: of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

Pharmacokinetics results. Supplemental results for pharmacokinetics analysis. Table S3: Summary of p...

Additional file 3: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Table S1. Overall study population and biomarker population characteristics. (PDF 171 kb

Additional file 6: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Table S2. Rates of pathological complete response (pCR) reported across 15 published neoadjuvant cli...

Additional file 1: of Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Nadine Norton (488827)
Nicholas Fox (5392982)
Christie-Ann McCarl (5392979)
Kathleen Tenner (5392988)
Karla Ballman (404207)
Courtney Erskine (5392991)
Brian Necela (3664780)
Donald Northfelt (4609261)
Winston Tan (5392994)
Carmen Calfa (5392985)
Mark Pegram (3568463)
Gerardo Colon-Otero (3472709)
Edith Perez (3439139)
Raphael Clynes (326829)
Keith Knutson (376781)

June 2018

Table S1. Comparison of clinical characteristics of study patients and remaining N9831 cohort. (DOCX...

Additional file 3: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

pCR prediction scores and their relationship with pCR (odds ratio and 95Â % confidence intervals). (...

Additional file 3: of From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Júlia Perera-Bel (4968799)
Barbara Hutter (420459)
Christoph Heining (4968805)
Annalen Bleckmann (318840)
Martina Fröhlich (2186257)
Stefan Fröhling (4968802)
Hanno Glimm (200902)
Benedikt Brors (14082)
Tim Beißbarth (31587)

March 2018

Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...

Additional file 1 of Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Abolghasem Allahyari (11091869)
Ali Ehsanpour (13759523)
Nafiseh Ansarinejad (13173555)
Valiollah Mehrzad (13759526)
Behjat Kalantari (13173549)
Jahangir Raafat (13173552)
Mojtaba Ghadiany (13759529)
Farhad Shahi (9162383)
Behrooz Gharib (6578189)
Vahid Moazed (13173558)
Adnan Khosravi (13759532)
Mir Hossein Mirpour (13759535)
Sina Salari (9162389)
Seyedmohammadreza Mortazavizadeh (13759538)
Amirabbas Nekoyi (13759541)
Mohsen Khani (10840030)
Alireza Sadeghi (13759544)
Sirus Gharib (13759547)
Alireza Bary (13759550)
Mehrzad Mirzania (13173573)
Shirin Haghighat (13173570)
Seyed Mohsen Razavi (12223145)
Seyed Amir Hossein Emami (13584340)
Mehran Hosseinzadeh (9340120)
Mahdi Mirbolouk (13759553)
Sanambar Sadighi (4330228)
Abdolali Shahrasbi (13759556)
Ali Esfahani (13759559)
Masoumeh Gity (3700750)
Nassim Anjidani (9850450)
Hamidreza Kafi (13173585)
Safa Najafi (13759562)

September 2022

Additional file 1: Supp. Table 1. Breast cancer type. Supp. Table 2. Tumor and Lymph node distributi...

Additional file 2: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

Results of the multivariate analysis of clinicopathological factors influencing the prediction of pC...

Additional file 1: of Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Elaine Reguera-NuĂąez (6201248)
Ping Xu (122619)
Annabelle Chow (738948)
Shan Man (445984)
Frank Hilberg (6201242)
Robert Kerbel (5171546)

January 2019

Table S1. Phase II and III Clinical trials evaluating Atezolizumab in combination with Bevacizumab (...

Additional file 3: Table S3. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

Adverse events (all grades [âĽ5%]) requiring dose adjustment/interruption, regardless of causality,...

Additional file 1: Table S1. of A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Amabel Tan (302589)
Anne Goubier (3541961)
Holbrook Kohrt (3541958)

November 2015

Vaccine categories in trial completed prior to 2013, or with planned completion post 2013. Table S2....

Additional file 1: of Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

Marcus Vetter (3422660)
Julia Landin (5997692)
Barbara Szczerba (5997695)
Francesc Castro-Giner (5659600)
Sofia Gkountela (191896)
Cinzia Donato (5997698)
Ilona Krol (5997701)
Ramona Scherrer (5997704)
Catharina Balmelli (5997707)
Alexandra Malinovska (5997710)
Alfred Zippelius (805066)
Christian Kurzeder (5997713)
Viola Heinzelmann-Schwarz (390410)
Walter Weber (5997716)
Christoph Rochlitz (190083)
Nicola Aceto (5997719)

November 2018

Table S1. Drug classification. The table shows the drug classification used for the analysis, groupi...

Additional file 2: of Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Giampaolo Bianchini (516649)
Astrid Kiermaier (3739423)
Giulia Bianchi (3739441)
Young-Hyuck Im (2266708)
Tadeusz Pienkowski (3739432)
Mei-Ching Liu (3739429)
Ling-Ming Tseng (526534)
Mitch Dowsett (645)
Lila Zabaglo (3537764)
Sarah Kirk (3739426)
Tania Szado (3739435)
Jennifer Eng-Wong (3739438)
Lukas Amler (73009)
Pinuccia Valagussa (58502)
Luca Gianni (516651)

February 2017

Figure S1. Relationship between biomarkers and pCR by treatment group and estrogen receptor status. ...

Additional file 5: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Figure S3. Effect of 14 single genes on pathological complete response (pCR) adjusting for clinicopa...

Additional file 1: of A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Patrick Schöffski (125074)
Sara Cresta (5722382)
Ingrid Mayer (5722385)
Hans Wildiers (146595)
Silvia Damian (5722388)
Steven Gendreau (3350078)
Isabelle Rooney (5722391)
Kari Morrissey (5722394)
Jill Spoerke (5722397)
Vivian Ng (38767)
Stina Singel (5722400)
Eric Winer (5722403)

September 2018

Table S1. All-grade AEs related to any study drug occurring in ≥ 15% of all patients and correspondi...

Additional file 4: of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

Pharmacokinetics results. Supplemental results for pharmacokinetics analysis. Table S3: Summary of p...

Additional file 3: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Table S1. Overall study population and biomarker population characteristics. (PDF 171 kb

Additional file 6: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Table S2. Rates of pathological complete response (pCR) reported across 15 published neoadjuvant cli...

Additional file 1: of Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Nadine Norton (488827)
Nicholas Fox (5392982)
Christie-Ann McCarl (5392979)
Kathleen Tenner (5392988)
Karla Ballman (404207)
Courtney Erskine (5392991)
Brian Necela (3664780)
Donald Northfelt (4609261)
Winston Tan (5392994)
Carmen Calfa (5392985)
Mark Pegram (3568463)
Gerardo Colon-Otero (3472709)
Edith Perez (3439139)
Raphael Clynes (326829)
Keith Knutson (376781)

June 2018

Table S1. Comparison of clinical characteristics of study patients and remaining N9831 cohort. (DOCX...

Additional file 3: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

pCR prediction scores and their relationship with pCR (odds ratio and 95Â % confidence intervals). (...

Additional file 3: of From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Júlia Perera-Bel (4968799)
Barbara Hutter (420459)
Christoph Heining (4968805)
Annalen Bleckmann (318840)
Martina Fröhlich (2186257)
Stefan Fröhling (4968802)
Hanno Glimm (200902)
Benedikt Brors (14082)
Tim Beißbarth (31587)

March 2018

Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...

Additional file 1 of Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Abolghasem Allahyari (11091869)
Ali Ehsanpour (13759523)
Nafiseh Ansarinejad (13173555)
Valiollah Mehrzad (13759526)
Behjat Kalantari (13173549)
Jahangir Raafat (13173552)
Mojtaba Ghadiany (13759529)
Farhad Shahi (9162383)
Behrooz Gharib (6578189)
Vahid Moazed (13173558)
Adnan Khosravi (13759532)
Mir Hossein Mirpour (13759535)
Sina Salari (9162389)
Seyedmohammadreza Mortazavizadeh (13759538)
Amirabbas Nekoyi (13759541)
Mohsen Khani (10840030)
Alireza Sadeghi (13759544)
Sirus Gharib (13759547)
Alireza Bary (13759550)
Mehrzad Mirzania (13173573)
Shirin Haghighat (13173570)
Seyed Mohsen Razavi (12223145)
Seyed Amir Hossein Emami (13584340)
Mehran Hosseinzadeh (9340120)
Mahdi Mirbolouk (13759553)
Sanambar Sadighi (4330228)
Abdolali Shahrasbi (13759556)
Ali Esfahani (13759559)
Masoumeh Gity (3700750)
Nassim Anjidani (9850450)
Hamidreza Kafi (13173585)
Safa Najafi (13759562)

September 2022

Additional file 1: Supp. Table 1. Breast cancer type. Supp. Table 2. Tumor and Lymph node distributi...

Additional file 2: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

Results of the multivariate analysis of clinicopathological factors influencing the prediction of pC...

Additional file 1: of Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Elaine Reguera-NuĂąez (6201248)
Ping Xu (122619)
Annabelle Chow (738948)
Shan Man (445984)
Frank Hilberg (6201242)
Robert Kerbel (5171546)

January 2019

Table S1. Phase II and III Clinical trials evaluating Atezolizumab in combination with Bevacizumab (...

Additional file 3: Table S3. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

Adverse events (all grades [âĽ5%]) requiring dose adjustment/interruption, regardless of causality,...

Additional file 1: Table S1. of A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Amabel Tan (302589)
Anne Goubier (3541961)
Holbrook Kohrt (3541958)

November 2015

Vaccine categories in trial completed prior to 2013, or with planned completion post 2013. Table S2....

Additional file 1: of Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

Marcus Vetter (3422660)
Julia Landin (5997692)
Barbara Szczerba (5997695)
Francesc Castro-Giner (5659600)
Sofia Gkountela (191896)
Cinzia Donato (5997698)
Ilona Krol (5997701)
Ramona Scherrer (5997704)
Catharina Balmelli (5997707)
Alexandra Malinovska (5997710)
Alfred Zippelius (805066)
Christian Kurzeder (5997713)
Viola Heinzelmann-Schwarz (390410)
Walter Weber (5997716)
Christoph Rochlitz (190083)
Nicola Aceto (5997719)

November 2018

Table S1. Drug classification. The table shows the drug classification used for the analysis, groupi...

Additional file 2: of Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Giampaolo Bianchini (516649)
Astrid Kiermaier (3739423)
Giulia Bianchi (3739441)
Young-Hyuck Im (2266708)
Tadeusz Pienkowski (3739432)
Mei-Ching Liu (3739429)
Ling-Ming Tseng (526534)
Mitch Dowsett (645)
Lila Zabaglo (3537764)
Sarah Kirk (3739426)
Tania Szado (3739435)
Jennifer Eng-Wong (3739438)
Lukas Amler (73009)
Pinuccia Valagussa (58502)
Luca Gianni (516651)

February 2017

Figure S1. Relationship between biomarkers and pCR by treatment group and estrogen receptor status. ...

Additional file 5: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá (6188426)
Mafalda Oliveira (6175118)
Tomás Pascual (6188429)
Jose Perez-Garcia (6188432)
Xavier Gonzàlez (6188435)
Jordi Canes (6188438)
Laia Paré (3530123)
Isabel Calvo (6188441)
Eva Ciruelos (2794504)
Montserrat Muñoz (474766)
Juan Virizuela (6188444)
Isabel Ruiz (6188447)
Raquel Andrés (160112)
Antonia Perelló (6188450)
Jerónimo Martínez (6188453)
Serafín Morales (4000805)
Mercedes Marín-Aguilera (95548)
Débora Martínez (6188456)
Juan Quero (6188459)
Antonio Llombart-Cussac (6188462)
Aleix Prat (3530144)

January 2019

Figure S3. Effect of 14 single genes on pathological complete response (pCR) adjusting for clinicopa...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Abstract

Extracted data

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Abstract

Extracted data

Topics

Related items

Topics

Related items